Author: BioactiveCompoundLibrary

The lipid composition and the curvature of biological membranes are limiting steps for peptide interactions with living cells and liposomes. Cholesterol has been proven to be essential for filovirus replication, and the entry of the Ebola and Marburg viruses is inhibited after cholesterol depletion of the target cells. In cells not depleted of cholesterol, viral proteins co-localize with caveolin after internalization. Caveolae are vesicles enriched with cholesterol and sphingolipids and have been shown to be involved in a wide range of biological events such as cellular entry by certain viruses. In this work, we depleted cholesterol from cells to understand its importance in the mechanism of membrane fusion, an early step in the Ebola infection cycle. Since Vero and BHK-21 mammalian cells are permissive to infection mediated by the Ebola virus, initial attempts were performed by using those cells. b-cyclodextrins were used to since they are very effective to selectively extract cholesterol from membranes of intact cells without binding or insertion into the plasma membrane. Vero and BHK-21 cells were treated with increasing concentrations of MbCD for 30 min at 37uC and then assayed for cholesterol quantification. As shown in Fig. 1A, cholesterol depletion was dose-dependent for Vero and BHK-21 cells. In addition, insect cells, previously grown in medium with cholesterol, were assayed as a cellular control of low cholesterol content cells. Insect cells are cholesterol auxotrophs and can be depleted of cholesterol by growth in delipidated serum. As observed in Fig. 1A, the cholesterol content of C6/36 cells was maintained after incubation with up to 12 mM MbCD. However, upon incubation with 20 and 24 mM MbCD, it was not possible to detect cholesterol due to the low cell adhesion induced by depletion. To determine the effect of MbCD on cell viability, Vero, BHK-21 and C6/36 cells were incubated in the absence or in the presence of MbCD. At the same time we added MTT reagents to prevent cellular loss during the washing step. In general, insect and mammalian cell monolayers were intact after 30 min incubation with up to 16 or 24 mM of MbCD, respectively. Fig. 1B shows that insect cells were more affected by cholesterol depletion than mammalian cells. Indeed, 16 mM MbCD was able to decrease 50–60% of cholesterol in mammalian and insect cells but only affected the viability of insect cells. Thus, our results showed that some different MbCD concentrations can induce similar levels of cholesterol depletion but different responses in cellular viability. In our studies, low MbCD concentrations, which cause depletion of cholesterol but do not affect the cellular viability, were chosen to examine the role played by cholesterol during protein-membrane interaction. Previous studies had shown that low BYL719 endosomal pH is required for infection and cell-cell fusion mediated by Ebola virus GP and that low pH is required for optimal functioning of cathepsin B and L.

Saliva-based translational research and LEE011 technology is now at a mature juncture and can be evaluated to determine its utility for breast cancer detection. Explorative studies have evaluated the potential use of salivary proteins such as c-erbB-2, VEGF, EGF, and CEA in the initial detection and/ or follow-up screening for the recurrence of breast cancer. However, these investigations were not based on biomarker discoveries from saliva specimens, rather they were testing blood biomarkers in saliva. Here, we report the use of transcriptomic and proteomic approaches to discover and pre-validate biomarkers in saliva for the noninvasive detection of breast cancer. Our results demonstrate significant differences in salivary transcriptomic and proteomic profiles between breast cancer patients and controls. The discovered salivary biomarkers possess discriminatory power for the detection of breast cancer, with high specificity and sensitivity. Early detection of breast cancer offers the promise of easier treatment and improved survival. Conventional screening has a less-than-desirable sensitivity and specificity. Our long-term goal is to develop a saliva-based noninvasive tool for the early detection of breast cancer. We envision a clinical context in which a salivary test may enable clinicians to detect breast cancer earlier, and reduce the number of unnecessary biopsies, in a cost-effective manner. The purpose of this study, which is an essential step toward attaining our long-range goal, is to evaluate the potential utilityof salivary transcriptomes and proteomes for breast cancer detection. We applied two high-throughput technologies in order to assess 1) whether the salivary transcriptome and proteome profiles change with the onset of breast cancer, and 2) whether discriminatory biomarkers can be identified and validated. By addressing both questions, our profiling results, and further independent validation of the discovered biomarkers, will open new research directions and support the idea that saliva is a useful biomarker source for breast cancer detection. The salivary transcriptome is a novel diagnostic alphabet we have explored for discovering breast cancer biomarkers. Salivary transcriptional profiling technology has been successfully applied for discovering detection biomarkers of resectable pancreatic cancer. Consistent with that study, high-throughput profiling revealed significant variations in gene signature profiles between the breast cancer patients and the controls, demonstrating that the salivary transcriptome is an informative biomarker source for systemic cancer detection. The gene ontology analysis could categorize the 1301 up/down-regulated genes into various biological processes based on their known roles or functions. Proteomic profiling, without independent validation, has been recently performed for discovering salivary biomarkers using stimulated whole saliva.

RhoBTB3 is a member of the RHOBTB subfamily of Rho GTPases that play a role in mediating cell size, proliferation, apoptosis, PI-103 survival, polarity, call adhesion and membrane trafficking. Recent studies have suggested that RhoB is involved in tumor suppression. These studies suggested that RhoB was detected in normal tissue yet its expression was dramatically lost during cancer progression in lung and head and neck squamous cell carcinoma. In line with these findings, high expression of RhoB was associated with favorable outcome in bladder cancer. In our study, we suggested that RhoBTB3 might serve as a potential tumor marker for good prognosis in USC. RAS association domain family 7 is located at 11p15.5 and it belongs to the Ras-domain family of ten members that are implicated in various cellular mechanisms including apoptosis, cell cycle control, and microtubule stabilization. They are downregulated by epigenetic mechanisms, indicating the potential role of a tumor suppressor gene. However, this does not currently exist in RASSF7. Recently RASSF7 was found in numerous tissues and knocking down RASSF7 function resulted in blocking spindle formation, triggering a mitotic arrest, nuclear breakdown and apoptosis. This suggests the possibility that RASSF7 could have a role in promoting cancer cell development. In our study the under-expression of RASSF7 in USC correlated with good prognosis and the detection of RASSF7 silencing by methylation study could have potential clinical use for USC prognosis and treatment. Finally, Fibulin1, mapped on 22q13.3 gene, belongs to a family of secreted glycoproteins. Fibulin family has been shown to modulate cell morphology, growth, adhesion and motility. In particular, FBLN1 appeared to have a role in inhibiting cell adhesion, spreading, motility and invasion in human cancer cells. In vivo studies showed increased FBLN1 expression in ovarian and breast carcinomas. Others had showed its downregulation in prostate and gastric cancer. Therefore, speculation still exists regarding FBLN1 as a tumor-suppressor gene or an oncogene or it might even have dual functions. In our study, the over-expression of the FBLN1 protein was observed for good prognosis in EAC. One limitation of this study is the relatively small sample size which does not provide us enough power for statistical analysis of expression levels of DEGs and clinical characteristics. The result should be interpreted with caution because of the small sample size and undetermined molecular mechanisms of novel DEGs. Nevertheless, novel DEGs found in our studies, once narrowed down and verified in future studies with larger cohort, might have potential prognostic and therapeutic effects in each of EAC and USC. In conclusion, although the sample size was small for a definite conclusion, we believe that our findings shed meaningful insights into the clinical study of endometrial cancer patients that warrant further investigation.

KOTg and the KO mice were considerably debilitated by the age of 9-10 months as previously reported for aB-crystallin/HspB2deficient mice. At this age, WTTg mice do not have significant levels of plaque pathology and plaques develop only in mice older than 10-12 months of age. Immunohistochemical examination of mice brains at 7 months revealed no plaques under our experimental conditions. However, it is thought that plaques may not be causative and others have shown that decreased dendritic spine density, impaired long-term potentiation, and behavioral deficits occurred many months before detectable plaques. We observed a modest locomotor deficit in WTTg mice by open field tests suggesting that the expression of hAPP affected muscle function. In Tg2576 mice, expression of the APP transgene has been observed in muscle tissue where the function of aB-crystallin and HspB2 is expected to be crucial. The presence of amyloid oligomers in muscle cells has been shown to have potent toxicity. Thus, the high degree of synergistic toxic effects of aB-crystallin/HspB2 loss and transgene expression in the skeletal muscle precluded the examination of plaque pathology at later ages. Because sHsps block the fibrillization and toxicity of Ab it is suggested that in the Y-27632 absence of aBcrystallin/HspB2 enhanced Ab toxicity may contribute to the manifestation of the synergistic phenotypes. An alternative explanation for the locomotion defect is that since APP is expressed throughout the brain in this mouse, it might contribute to deficits in the brain motor centers. The locomotion defects observed in the WTTg mice are important because these transgenic mice are routinely used in learning and memory tests that involve locomotion. In agreement with our observations, motor deficits in Tg2576 have been observed at 6–7 months in a recent publication. No significant perturbation in the motor reflexes was observed in WTTg mice as the mice could perceive and respond to thermal stimulus in the supraspinal nociception test. However, reduced chaperone levels in the transgenic mice produced a sensory defect suggesting that this synergism also affected nociception. In the WTTg mice, we also observed a significant limitation in their ability to associate mild aversive stimulus with the environmental context but not with an auditory cue. This difference in associative learning can be interpreted as follows – Contextual learning may be based on weak associations between the footshock and diverse signals and thereby differences between WT and WTTg are manifested significantly. It has been thought that animals may associate only a subset of contextual elements, which leads to weak associative learning. The inability of WTTg to associate and integrate the complex contextual signals with the aversive stimulus indicates a reduced hippocampal function. Contextual associative learning deficit in Tg2576 has been previously observed.

The 5-year survival rates are estimated to be 50% for stage II, 20% for stage III and 5-10% for stage IV disease. Molecular genetic data supports the idea that endometrial carcinomas are likely to develop through a multi-step process of oncogene activation and tumor suppressor gene inactivation. In addition, studies have demonstrated that molecular alterations are specific for type I and type II endometrial carcinoma. Type I cancer is BAY 43-9006 characterized by mutation of PTEN, and defects in DNA mismatch repair . Type II cancers are characterized by p53 and Her-2/neu mutations. However, these gene alterations alone do not explain the different behavior and outcomes in type I and type II cancers. Most of the studies using cDNA microarray analysis have only focused on defining differential gene expression among different histologic types of endometrial cancer. The aims of this study were focused on stages and outcomes in two histologic types: EAC and USC. The purpose was to identify the difference in gene expression patterns in late stages versus early stages in each of the two types and in patients with good prognosis versus poor prognosis in EAC and USC, respectively. The main focus of the study is to identify and evaluate gene expression patterns in late vs. early stage and good vs. poor prognosis in each of endometrioid and serous types. Using the Illumina HumanHT-12 v3 microarray, we found 274 and 111 stage-related DEG in each of USC and EAC respectively. However, we were not able to find any overlap for DEGs with at least 2 fold changes in late stages EAC and USC versus early stages EAC and USC, indicating that tumor progression of different endometrial adenocarcinoma subtypes might be characterized by distinct gene expression signatures. In addition, we found 112 DEGs that are differently expressed for good vs. poor prognosis in EAC and 135 DEGs in USC. Only 1 DEGs is shared by the 135 prognosis-derived DEGs in USC and the 112 prognosis-derived DEGs in EAC. These findings indicate that tumor outcome of different endometrial adenocarcinoma subtypes might also characterized by distinct gene expression signatures. In other words, DEGs derived from USC might exclusively contain USC-specific prognosis biomarkers, while the DEGs derived from EAC might exclusively contain EAC-specific prognosis biomarkers. This confirms the existence of a distinct gene expression signature between endometrioid and serous carcinoma as previously seen, and that there is a distinct gene expression signature driving late vs. early stages in each of these two types. Additionally, the lack of overlap between stage-related and prognosis-related DEG sets in each subtype is of particular interest suggesting genes that drive and control stages might be distinct from the genes that drive and control outcomes. As a result, it would be of paramount interest to identify tailored biomarkers for outcome prediction and treatment modalities in patients with endometrial adenocarcinoma.